Study guide

9.1 Inotropes, Vasopressors, and Inodilators in Perioperative Care

EDAIC Part I European Diploma in Anaesthesiology and Intensive Care

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: The EDAIC Part I Examination

1.1 EDAIC Part I Exam Format, Scoring and Multiple True/False Strategy

2 Chapter 2: Anatomy for Anaesthesia and Intensive Care

2.1 Functional Anatomy of the Upper Airway, Larynx, and Tracheobronchial Tree 2.2 Neuraxial Anatomy: Spine, Spinal Cord, Meninges, and Spaces 2.3 Vascular Anatomy for Central and Peripheral Cannulation 2.4 Peripheral Nerve Plexuses and Autonomic Nervous System Pathways 2.5 Thoracic Anatomy: Chest Wall, Intercostal Spaces, Pleura, Mediastinum and Heart

3 Chapter 3: Respiratory and Cardiovascular Physiology

3.1 Respiratory Mechanics, Lung Volumes, and Work of Breathing 3.2 Ventilation-Perfusion Relationships, Shunt, and Gas Exchange 3.3 Control of Breathing, Hypoxia, Altitude and Hyperbaric Physiology 3.4 Cardiac Cycle, Electrophysiology, and Ventricular Function 3.5 Vascular Resistance, Microcirculation, and Systemic Hemodynamics

4 Chapter 4: Neurophysiology, Renal, Hepatic and Acid-Base Physiology

4.1 Cerebral Blood Flow, Intracranial Pressure, and CSF Dynamics 4.2 Renal Physiology, Glomerular Filtration, and Tubular Transport 4.3 Hepatic Blood Flow, Metabolism, and Clearance 4.4 Acid-Base Regulation, Buffering Systems, and Stewart Approach

5 Chapter 5: Endocrine and Haematological Physiology

5.1 Endocrine Physiology and the Neuroendocrine Stress Response 5.2 Haemostasis Physiology, Coagulation Testing and Inherited Bleeding Disorders

6 Chapter 6: Special Patient Physiology: Maternal, Paediatric and Geriatric

6.1 Maternal Physiological Adaptations to Pregnancy and Uteroplacental Flow 6.2 Neonatal and Paediatric Physiological Differences 6.3 Physiological Changes of Ageing and Thermoregulation

7 Chapter 7: General Pharmacological Principles and Inhalational Anaesthetics

7.1 Pharmacokinetic Principles, Compartmental Models, and Clearance 7.2 Pharmacodynamic Mechanisms, Receptor Theory, and Drug Interactions 7.3 Physical Properties, Uptake, and Distribution of Volatile Anaesthetics 7.4 Minimum Alveolar Concentration (MAC), Organ Effects, and Toxicity

8 Chapter 8: Intravenous Agents, Neuromuscular Blockade and Analgesics

8.1 Intravenous Induction Agents: Propofol, Etomidate, Ketamine, and Barbiturates 8.2 Neuromuscular Blocking Agents: Depolarizing and Non-Depolarizing Drugs 8.3 Neuromuscular Monitoring and Reversal: Anticholinesterases and Sugammadex 8.4 Opioid Pharmacology, Receptors, and Non-Opioid Analgesic Agents

9 Chapter 9: Cardiovascular Drugs, Autonomic Pharmacology and Local Anaesthetics

9.1 Inotropes, Vasopressors, and Inodilators in Perioperative Care 9.2 Antiarrhythmic, Antihypertensive, and Beta-Adrenergic Antagonist Drugs 9.3 Local Anaesthetic Pharmacology, Toxicity (LAST), and Lipid Emulsion Therapy

10 Chapter 10: Haematological and Internal Medicine Pharmacology

10.1 Anticoagulant, Antiplatelet and Haemostatic Drugs and Their Reversal 10.2 Internal Medicine Drugs: Endocrine, Respiratory, Psychiatric and Antiepileptic Agents and Their Anaesthetic Interactions

11 Chapter 11: Physics, Clinical Measurement and Medical Equipment

11.1 Physical Gas Laws, Fluid Dynamics, and Resistance Principles 11.2 Anaesthetic Machines, Gas Supply Pipelines, Cylinders, and Safety Mechanisms 11.3 Breathing Systems, Vaporizer Mechanics, and Scavenging Systems 11.4 Invasive and Non-Invasive Hemodynamic and Respiratory Monitoring

12 Chapter 12: Electrical Safety, Temperature, Humidity and Gas Analysis

12.1 Electricity, Electrical Safety, Diathermy, Defibrillation, Implanted Devices and Fire 12.2 Temperature Measurement, Humidity, Gas Analysis and SI Units

13 Chapter 13: Biostatistics, Clinical Trials and Evidence Appraisal

13.1 Descriptive Statistics, Distributions, and Parametric vs Non-Parametric Tests 13.2 Hypothesis Testing, Power, Type I/II Errors, and Confidence Intervals 13.3 Clinical Study Designs, Bias, and Diagnostic Test Performance (Sensitivity, Specificity, ROC)

14 Chapter 14: General Anaesthesia, Preoperative Evaluation and Airway Management

14.1 Preoperative Risk Assessment, Cardiovascular Risk Indices, and Fasting Guidelines 14.2 The Difficult Airway: Assessment, Algorithms, and Rescue Oxygenation 14.3 Intraoperative Fluid Therapy, Goal-Directed Hemodynamics, and Blood Conservation 14.4 Post-Anaesthesia Care Unit (PACU) Management, Emergence, and Postoperative Nausea/Vomiting

15 Chapter 15: Coexisting Disease and Preoperative Investigations

15.1 Interpreting Investigations: ECG, Chest Radiograph, Lung Function and Blood Tests 15.2 Coexisting Disease I: Asthma, COPD, Obstructive Sleep Apnoea, Obesity, Liver and Renal Disease 15.3 Endocrine Disease and Emergencies: Diabetes, DKA and HHS, Thyroid, Adrenal, Phaeochromocytoma and Carcinoid 15.4 Coexisting Disease II: Neuromuscular and Neurological Disease

16 Chapter 16: Subspecialty Anaesthesia: Cardiothoracic, Vascular and Neuroanaesthesia

16.1 Anaesthesia for Cardiac Surgery and Cardiopulmonary Bypass Management 16.2 Thoracic Anaesthesia, One-Lung Ventilation, and Major Vascular Surgery 16.3 Neuroanaesthesia: Craniotomy, Sitting Position, and Traumatic Brain Injury

17 Chapter 17: Obstetric, Paediatric and Ambulatory Anaesthesia

17.1 Obstetric Analgesia and Anaesthesia: Labour, Caesarean Delivery, and High-Risk Conditions 17.2 Paediatric Anaesthesia: Induction, Airway Management, and Emergencies 17.3 Ambulatory Day-Surgery Selection, Premedication, and Elderly Patient Anaesthesia

18 Chapter 18: Anaesthetic Complications and Specialty Settings

18.1 Anaesthetic Complications: Accidental Awareness, Aspiration, Positioning Injuries, Visual Loss and Dental Damage 18.2 Anaesthesia for ENT and Laser Airway Surgery, Ophthalmic Surgery, and Laparoscopic and Robotic Surgery

19 Chapter 19: Regional Anaesthesia and Acute/Chronic Pain Management

19.1 Neuraxial Techniques: Spinal, Epidural, and Caudal Anaesthesia 19.2 Upper and Lower Limb Peripheral Nerve and Fascial Plane Blocks 19.3 Multimodal Acute Postoperative Pain Management and ERAS Pathways 19.4 Chronic and Neuropathic Pain Syndromes and Interventional Management 19.5 Palliative Symptom Control, Psychological Aspects of Pain and Multidisciplinary Pain Management

20 Chapter 20: Intensive Care Medicine: Ventilation, Shock and Organ Support

20.1 Acute Respiratory Distress Syndrome (ARDS) and Mechanical Ventilation Strategies 20.2 Sepsis-3 Definitions, Septic Shock, and Hemodynamic Resuscitation 20.3 Acute Kidney Injury, Indications for Dialysis, and Continuous Renal Replacement Therapy 20.4 ICU Sedation, Delirium, Weaning, and Brain Death Determination

21 Chapter 21: Intensive Care Medicine: Admission, Nutrition, Infection and Electrolytes

21.1 ICU Admission, Severity Scoring, Nutrition and Routine Prophylaxis 21.2 Antimicrobial Therapy, Stewardship and ICU-Acquired Infections 21.3 Electrolyte Disorders: Sodium, Potassium, Calcium, Magnesium and Phosphate

22 Chapter 22: Intensive Care and Emergency Medicine: Neurocritical Care, Poisoning and Cardiorespiratory Emergencies

22.1 Neurocritical Care: Subarachnoid Haemorrhage, Stroke, Status Epilepticus and Acute Neuromuscular Failure 22.2 Acute Poisoning: Toxidromes, Decontamination and Specific Antidotes 22.3 Acute Cardiorespiratory Emergencies: Pulmonary Embolism, Acute Severe Asthma and COPD, Non-Invasive Support and Acute Heart Failure

23 Chapter 23: Resuscitation, Perioperative Emergencies and Professional Ethics

23.1 Advanced Life Support (ALS) Guidelines and Perioperative Cardiac Arrest 23.2 Perioperative Crises: Malignant Hyperthermia and Severe Anaphylaxis 23.3 Major Trauma, Hemorrhagic Shock, and Massive Transfusion Protocols 23.4 Professional Ethics, Informed Consent, Patient Safety, and Helsinki Declaration

24 Chapter 24: Newborn, Paediatric and Obstetric Emergencies

24.1 Newborn Life Support and Paediatric Life Support 24.2 Obstetric Emergencies: Maternal Collapse, Amniotic Fluid Embolism, Uterine Inversion and Resuscitative Hysterotomy

25 Chapter 25: Burns, Environmental Emergencies and Patient Transport

25.1 Burns, Inhalation Injury, Drowning, Hypothermia, Heat Illness and Decompression Illness 25.2 Prehospital Care and Intra- and Inter-Hospital Transport of the Critically Ill

9.1 Inotropes, Vasopressors, and Inodilators in Perioperative Care

Key Takeaways Explain This Topic AI

Adrenergic receptors transduce signals via distinct G-protein pathways: α 1 \alpha_1 α 1 ​ couples to G q G_q G q ​ (activating phospholipase C to generate IP 3 \text{IP}_3 IP 3 ​ and DAG \text{DAG} DAG , elevating intracellular C a 2 + Ca^{2+} C a 2 + and triggering vascular smooth muscle contraction), α 2 \alpha_2 α 2 ​ to G i G_i G i ​ (inhibiting adenylyl cyclase, lowering cAMP \text{cAMP} cAMP to mediate presynaptic auto-inhibition, sedation, and analgesia), β 1 \beta_1 β 1 ​ to G s G_s G s ​ (activating adenylyl cyclase, elevating cAMP \text{cAMP} cAMP and stimulating protein kinase A to phosphorylate sarcolemmal L-type C a 2 + Ca^{2+} C a 2 + channels and phospholamban, enhancing inotropy, chronotropy, dromotropy, and lusitropy), while β 2 \beta_2 β 2 ​ couples to G s G_s G s ​ (where PKA-mediated phosphorylation and inhibition of myosin light chain kinase promotes vasodilation and bronchodilation).

Epinephrine demonstrates concentration-dependent receptor selectivity: low-dose infusions ( 0.01 − 0.05 mcg/kg/min 0.01-0.05\text{ mcg/kg/min} 0.01 − 0.05 mcg/kg/min ) stimulate predominantly high-affinity β 1 \beta_1 β 1 ​ and vascular β 2 \beta_2 β 2 ​ receptors, increasing cardiac output while decreasing systemic vascular resistance; higher doses ( > 0.1 mcg/kg/min >0.1\text{ mcg/kg/min} > 0.1 mcg/kg/min ) recruit α 1 \alpha_1 α 1 ​ receptors, producing intense systemic vasoconstriction; its prominent metabolic effects include hyperglycemia and hyperlactatemia driven by β 2 \beta_2 β 2 ​ -mediated stimulation of skeletal muscle glycogenolysis and aerobic glycolysis.

Norepinephrine acts as a potent, direct α 1 \alpha_1 α 1 ​ agonist with concurrent cardiac β 1 \beta_1 β 1 ​ stimulation and negligible β 2 \beta_2 β 2 ​ activity, making it the first-line vasopressor in septic and vasodilatory shock to restore systemic vascular resistance, mean arterial pressure, and cardiac preload via venous capacitance recruitment without inducing excessive tachycardia.

Inodilators provide positive inotropic support combined with systemic and pulmonary vasodilation: phosphodiesterase-3 (PDE3) inhibitors (milrinone, enoximone) prevent the breakdown of cAMP \text{cAMP} cAMP , augmenting myocardial contractility without increasing myocardial oxygen consumption to the extent of beta-agonists, but rely on renal elimination ( t 1 / 2 = 2 − 4 hours t_{1/2} = 2-4\text{ hours} t 1/2 ​ = 2 − 4 hours ); the calcium sensitizer levosimendan binds cardiac troponin C in a calcium-dependent manner and opens vascular ATP-sensitive potassium ( K ATP K_{\text{ATP}} K ATP ​ ) channels, yielding sustained hemodynamic improvements through its long-lived active metabolite OR-1896 ( t 1 / 2 ≈ 80 hours t_{1/2} \approx 80\text{ hours} t 1/2 ​ ≈ 80 hours ).

Arginine vasopressin (AVP) acts via V 1 V_1 V 1 ​ vascular receptors ( G q G_q G q ​ ) to restore vascular tone during severe acidemia and refractory vasoplegic shock when adrenergic receptors become uncoupled or desensitized; it spares the pulmonary vasculature by stimulating endothelial nitric oxide synthase and avoids catecholamine-induced tachyarrhythmias.

Last updated: October 2026

9.1 Inotropes, Vasopressors, and Inodilators in Perioperative Care

The hemodynamic stability of surgical and critically ill patients hinges on the precise pharmacological modulation of cardiac inotropy, chronotropy, systemic vascular resistance (SVR), and venous capacitance. Achieving optimal tissue perfusion while avoiding excessive myocardial oxygen consumption ( M V O 2 MVO_2 M V O 2 ​ ) requires comprehensive mastery of autonomic receptor signaling, intracellular second messenger cascades, and the pharmacodynamic profiles of sympathomimetic amines, inodilators, and non-adrenergic vasopressors.

1. Adrenergic and Dopaminergic Receptor Signal Transduction

Adrenergic and dopaminergic receptors belong to the superfamily of seven-transmembrane domain G-protein-coupled receptors (GPCRs). Their downstream physiological responses depend on the specific heterotrimeric G-protein (alpha, beta, gamma subunits) coupled to their intracellular loops. [ ADRENERGIC RECEPTOR SIGNALING ]

  • |
  • +--------------------------------+--------------------------------+
  • | | |
  • [ G_q-COUPLED ] [ G_i-COUPLED ] [ G_s-COUPLED ]
  • alpha_1 Receptors alpha_2 & D_2 Receptors beta_1, beta_2, & D_1 Receptors
  • | | |
  • v v v
  • Phospholipase C (PLC) Inhibits Adenylyl Cyclase Stimulates Adenylyl Cyclase
  • | | |
  • +-----+-----+ v v
  • | | Decreased cAMP Elevated cAMP
  • v v | |
  • IP_3 DAG Decreased PKA Activates PKA
  • | | | |
  • v v v v
  • Ca2+ Efflux Activates PKC Reduced Ca2+ Influx Phosphorylates Target
  • from SR Phosphorylates Enhanced K+ Efflux Proteins (CaV1.2, PLN,
  • Vascular Regulatory Presynaptic Autoinhibition RyR2, Troponin I,
  • Smooth Proteins Sedation, Analgesia, MLCK in smooth muscle)
  • Muscle Sympatholysis Inotropy / Vasodilation
  • Contraction
  • Alpha-1 ( α 1 \alpha_1 α 1 ​ ) Adrenoceptors

Signaling Cascade: α 1 \alpha_1 α 1 ​ receptors couple to the G q G_q G q ​ protein . Agonist binding activates phospholipase C- β \beta β (PLC) , which cleaves membrane phosphatidylinositol 4,5-bisphosphate ( PIP 2 \text{PIP}_2 PIP 2 ​ ) into two active second messengers:

Inositol 1,4,5-trisphosphate ( IP 3 \text{IP}_3 IP 3 ​ ): Diffuses through the cytoplasm to bind ligand-gated IP 3 \text{IP}_3 IP 3 ​ receptor channels on the sarcoplasmic reticulum (SR), triggering rapid efflux of stored calcium ( C a 2 + Ca^{2+} C a 2 + ) into the cytosol.

Diacylglycerol (DAG): Remains in the plasma membrane and, together with elevated cytosolic C a 2 + Ca^{2+} C a 2 + , activates protein kinase C (PKC) . PKC phosphorylates calponin, caldesmon, and other regulatory proteins, augmenting the sensitivity of contractile myofilaments to calcium.

Vascular Smooth Muscle Effect: Cytosolic C a 2 + Ca^{2+} C a 2 + binds calmodulin to form the C a 2 + -calmodulin Ca^{2+}\text{-calmodulin} C a 2 + -calmodulin complex, which activates myosin light chain kinase (MLCK) . MLCK phosphorylates the 20-kDa regulatory light chain of myosin, initiating actin-myosin cross-bridge cycling and intense arteriolar and venular vasoconstriction .

Alpha-2 ( α 2 \alpha_2 α 2 ​ ) Adrenoceptors

Signaling Cascade: α 2 \alpha_2 α 2 ​ receptors couple to the G i G_i G i ​ (inhibitory) protein . Activation inhibits adenylyl cyclase, depleting intracellular cyclic adenosine monophosphate ( cAMP \text{cAMP} cAMP ) and reducing protein kinase A (PKA) activity. In addition, the liberated G β γ G_{\beta\gamma} G β γ ​ dimer directly inhibits voltage-gated N-type calcium channels and activates inwardly rectifying potassium channels ( G I R K GIRK G I R K ), producing cellular hyperpolarization.

Physiological Actions:

Presynaptic Autoreceptors: Located on postganglionic sympathetic nerve terminals; activation exerts negative feedback inhibition, shutting down exocytotic release of endogenous norepinephrine.

Central Nervous System: Located in the locus coeruleus of the brainstem; activation suppresses central sympathetic outflow, inducing sedation, hypnosis, anxiolysis, and analgesia (the target of clonidine and dexmedetomidine).

Postsynaptic Vascular Receptors: Located on vascular smooth muscle; direct stimulation causes modest peripheral vasoconstriction (often observed as transient hypertension during rapid intravenous boluses of dexmedetomidine).

Beta-1 ( β 1 \beta_1 β 1 ​ ) Adrenoceptors

Signaling Cascade: β 1 \beta_1 β 1 ​ receptors couple to the G s G_s G s ​ (stimulatory) protein . Agonist binding triggers the G α s G_{\alpha s} G α s ​ subunit to activate membrane-bound adenylyl cyclase , converting adenosine triphosphate (ATP) to cAMP \text{cAMP} cAMP . Elevated cAMP \text{cAMP} cAMP binds the regulatory subunits of protein kinase A (PKA) , releasing active catalytic subunits that phosphorylate multiple critical cardiac targets:

L-type Calcium Channels ( C a V 1.2 Ca_V1.2 C a V ​ 1.2 ): Increases open-state probability, augmenting inward trigger C a 2 + Ca^{2+} C a 2 + current ( I Ca,L I_{\text{Ca,L}} I Ca,L ​ ) during Phase 2 of the cardiac action potential.

Ryanodine Receptors (RyR2): Augments calcium-induced calcium release (CICR) from the sarcoplasmic reticulum.

Phospholamban (PLN): Phosphorylation of phospholamban relieves its tonic inhibitory brake on the sarco/endoplasmic reticulum C a 2 + Ca^{2+} C a 2 + -ATPase (SERCA2a) pump. SERCA2a accelerates the reuptake of cytosolic calcium back into the SR during diastole.

Troponin I: Phosphorylation lowers myofilament calcium affinity, facilitating prompt cross-bridge detachment during relaxation.

Cardiovascular Effects:

Positive Inotropy: Increased contractile force due to augmented peak systolic intracellular C a 2 + Ca^{2+} C a 2 + .

Positive Chronotropy: Increased heart rate because cAMP binds directly to hyperpolarization-activated cyclic nucleotide-gated (HCN4) channels, increasing the pacemaker funny current ( I f I_f I f ​ ) in the sinoatrial (SA) node, while PKA augments I Ca,L I_{\text{Ca,L}} I Ca,L ​ .

Positive Dromotropy: Accelerated conduction velocity through the atrioventricular (AV) node via enhanced I Ca,L I_{\text{Ca,L}} I Ca,L ​ .

Positive Lusitropy: Accelerated myocardial relaxation during diastole (mediated primarily by phospholamban phosphorylation), preserving diastolic ventricular filling time during catecholamine-induced tachycardia.

Beta-2 ( β 2 \beta_2 β 2 ​ ) Adrenoceptors

Signaling Cascade: β 2 \beta_2 β 2 ​ receptors also couple to G s G_s G s ​ , stimulating adenylyl cyclase and generating cAMP \text{cAMP} cAMP to activate PKA.

Vascular and Bronchial Smooth Muscle Effect: Unlike cardiac myocytes, elevated cAMP \text{cAMP} cAMP and active PKA in smooth muscle promote relaxation (vasodilation and bronchodilation). PKA phosphorylates myosin light chain kinase (MLCK) , drastically reducing MLCK's affinity for the C a 2 + -calmodulin Ca^{2+}\text{-calmodulin} C a 2 + -calmodulin complex. Concurrently, PKA stimulates large-conductance calcium-activated potassium ( B K Ca BK_{\text{Ca}} B K Ca ​ ) channels, hyperpolarizing the cell membrane and reducing voltage-gated calcium entry, and enhances calcium extrusion via the plasma membrane C a 2 + Ca^{2+} C a 2 + -ATPase.

Dopaminergic ( D 1 D_1 D 1 ​ and D 2 D_2 D 2 ​ ) Receptors

D 1 D_1 D 1 ​ Receptors: Postsynaptic GPCRs coupled to G s G_s G s ​ . Located predominantly in renal, mesenteric, coronary, and cerebral vascular beds. Activation stimulates adenylyl cyclase, elevating cAMP \text{cAMP} cAMP and driving smooth muscle relaxation and vasodilation , which enhances renal cortical blood flow and promotes natriuresis.

D 2 D_2 D 2 ​ Receptors: Presynaptic GPCRs coupled to G i G_i G i ​ on sympathetic nerve terminals and autonomic ganglia. Activation inhibits adenylyl cyclase, attenuating exocytotic norepinephrine release and blunting sympathetic transmission.

2. Endogenous and Synthetic Catecholamines

Catecholamines are organic compounds consisting of an aromatic benzene ring with two adjacent hydroxyl groups (catechol) and an ethylamine side chain. Endogenous catecholamines are synthesized sequentially from the amino acid L-tyrosine: L-Tyrosine → Tyrosine hydroxylase L-DOPA → AADC Dopamine → Dopamine β -hydroxylase Norepinephrine → PNMT Epinephrine \text{L-Tyrosine} \xrightarrow{\text{Tyrosine hydroxylase}} \text{L-DOPA} \xrightarrow{\text{AADC}} \text{Dopamine} \xrightarrow{\text{Dopamine }\beta\text{-hydroxylase}} \text{Norepinephrine} \xrightarrow{\text{PNMT}} \text{Epinephrine} L-Tyrosine Tyrosine hydroxylase ​ L-DOPA AADC ​ Dopamine Dopamine β -hydroxylase ​ Norepinephrine PNMT ​ Epinephrine HO

  • \ CH - CH_2 - NH - R
  • | |
  • / OH
  • HO
  • [ Catecholamine Backbone ]
  • Epinephrine: R = -CH_3
  • Norepinephrine: R = -H
  • Isoproterenol: R = -CH(CH_3)_2 (bulky alkyl group -> pure beta)
  • Epinephrine (Adrenaline)

Receptor Profile: Non-selective agonist across α 1 , α 2 , β 1 , \alpha_1, \alpha_2, \beta_1, α 1 ​ , α 2 ​ , β 1 ​ , and β 2 \beta_2 β 2 ​ adrenoceptors.

Dose-Dependent Hemodynamics:

Low Dose ( 0.01 − 0.05 mcg/kg/min 0.01 - 0.05\text{ mcg/kg/min} 0.01 − 0.05 mcg/kg/min ): Predominant β 1 \beta_1 β 1 ​ and β 2 \beta_2 β 2 ​ stimulation. Produces marked positive inotropy, chronotropy, and lusitropy. Peripheral β 2 \beta_2 β 2 ​ stimulation outbalances α 1 \alpha_1 α 1 ​ tone, leading to a decrease in systemic vascular resistance (SVR) and diastolic blood pressure, while systolic blood pressure rises due to increased stroke volume. Pulse pressure widens and cardiac output increases.

High Dose ( > 0.1 − 0.2 mcg/kg/min >0.1 - 0.2\text{ mcg/kg/min} > 0.1 − 0.2 mcg/kg/min ): Overcoming α 1 \alpha_1 α 1 ​ agonism dominates over β 2 \beta_2 β 2 ​ -mediated vasodilation. Produces profound generalized vasoconstriction, elevated SVR, increased mean arterial pressure (MAP), and renal/splanchnic vascular constriction, while maintaining strong β 1 \beta_1 β 1 ​ cardiac contractility.

Metabolic Effects (The β 2 \beta_2 β 2 ​ Cascade):

Hyperlactatemia: Epinephrine stimulates skeletal muscle cell-surface β 2 \beta_2 β 2 ​ adrenoceptors coupled to adenylyl cyclase. The surge in cAMP \text{cAMP} cAMP activates glycogen phosphorylase, driving intense glycogenolysis and accelerated aerobic glycolysis . Pyruvate production rapidly outpaces the catalytic capacity of mitochondrial pyruvate dehydrogenase (PDH). Excess cytosolic pyruvate is converted directly to lactate by lactate dehydrogenase ( L D H LDH L DH ): Pyruvate + NADH + H + ⇌ LDH Lactate + NAD + \text{Pyruvate} + \text{NADH} + \text{H}^+ \xrightleftharpoons{\text{LDH}} \text{Lactate} + \text{NAD}^+ Pyruvate + NADH + H + LDH ​ Lactate + NAD + This mechanism represents Type B hyperlactatemia (aerobic, non-hypoxic lactate production), which must not be misconstrued as tissue hypoperfusion or cellular hypoxia.

Hyperglycemia: β 2 \beta_2 β 2 ​ receptor stimulation activates hepatic glycogenolysis and gluconeogenesis, while concurrent α 2 \alpha_2 α 2 ​ stimulation on pancreatic β \beta β -islet cells inhibits insulin secretion.

Hypokalemia: β 2 \beta_2 β 2 ​ receptor activation stimulates the electrogenic sarcolemmal Na + / K + \text{Na}^+/\text{K}^+ Na + / K + -ATPase pump in skeletal muscle, driving an inward shift of potassium ions from the extracellular to the intracellular space.

Norepinephrine (Noradrenaline)

Receptor Profile: Potent, direct α 1 \alpha_1 α 1 ​ and α 2 \alpha_2 α 2 ​ agonist, with moderate β 1 \beta_1 β 1 ​ inotropic activity and negligible β 2 \beta_2 β 2 ​ affinity.

Hemodynamic Profile: Norepinephrine is the first-line vasopressor in septic shock and vasodilatory hypotension (e.g., post-cardiopulmonary bypass vasoplegia, neuroaxial-induced sympathectomy). By stimulating α 1 \alpha_1 α 1 ​ receptors on resistance arterioles, it markedly elevates SVR and MAP.

Venous Capacitance and Preload Recruitment: Norepinephrine stimulates α 1 \alpha_1 α 1 ​ receptors on muscular venules and large veins (the splanchnic venous capacitance reservoir). Venoconstriction converts unstressed blood volume into stressed blood volume , increasing mean systemic filling pressure ( P msf P_{\text{msf}} P msf ​ ) and driving venous return to the right atrium. Through this mechanism, stroke volume and cardiac output are preserved or augmented despite increased afterload.

Reflex Chronotropy: Although direct β 1 \beta_1 β 1 ​ stimulation increases sinus node automaticity, the sudden surge in MAP activates arterial baroreceptors in the carotid sinus and aortic arch. Increased glossopharyngeal (CN IX) and vagal (CN X) afferent traffic to the nucleus tractus solitarius triggers compensatory vagal efferent discharge, which often counterbalances direct β 1 \beta_1 β 1 ​ tachycardia, producing a neutral or slightly reduced heart rate.

Phenylephrine

Receptor Profile: Pure, synthetic, direct-acting α 1 \alpha_1 α 1 ​ adrenoceptor agonist devoid of β \beta β -adrenergic activity.

Hemodynamic Profile: Produces rapid, dose-dependent arterial vasoconstriction and venoconstriction, increasing SVR, MAP, and central venous pressure ( C V P CVP C V P ).

Reflex Bradycardia and Cardiac Output Depression: In the absence of β 1 \beta_1 β 1 ​ inotropic stimulation, the robust baroreceptor reflex triggered by phenylephrine induces vagal bradycardia. Concurrently, the abrupt increase in left ventricular afterload without augmented inotropy frequently causes a 15% to 25% drop in cardiac output and stroke volume in patients with normal or depressed baseline ventricular function. It is primarily indicated for drug-induced vasodilatory hypotension with concurrent tachycardia.

Ephedrine

Receptor Profile: Mixed-acting sympathomimetic amine . It acts predominantly via an indirect mechanism , taken up by presynaptic neuronal uptake-1 transporters to displace and release endogenous stored norepinephrine from vesicles into the synaptic cleft. It also exerts weak, direct agonist actions at α 1 , β 1 , \alpha_1, \beta_1, α 1 ​ , β 1 ​ , and β 2 \beta_2 β 2 ​ receptors.

Hemodynamic Actions: Increases heart rate, stroke volume, SVR, and arterial blood pressure.

Tachyphylaxis: Repeated administration produces rapid pharmacological tolerance ( tachyphylaxis ). This phenomenon results from the progressive depletion of vesicular norepinephrine stores in peripheral sympathetic varicosities and down-regulation/desensitization of postsynaptic receptors.

Obstetric Use: Historically favored in obstetric anaesthesia for post-spinal hypotension because it preserves uterine artery blood flow via endogenous β 2 \beta_2 β 2 ​ stimulation and indirect vasopressor actions. However, modern evidence confirms that phenylephrine infusions maintain maternal arterial pressure with less fetal acidosis (ephedrine crosses the placenta and stimulates fetal metabolism, causing mild fetal hyperlactatemia).

Dopamine

Receptor Profile: Endogenous catecholamine displaying classic dose-dependent receptor affinity :

Low Dose ( 0.5 − 2.0 mcg/kg/min 0.5 - 2.0\text{ mcg/kg/min} 0.5 − 2.0 mcg/kg/min ): Selectively activates postsynaptic vascular D 1 D_1 D 1 ​ receptors in the renal, mesenteric, and coronary circulations, promoting vasodilation and natriuresis.

Intermediate Dose ( 2.0 − 10.0 mcg/kg/min 2.0 - 10.0\text{ mcg/kg/min} 2.0 − 10.0 mcg/kg/min ): Stimulates cardiac β 1 \beta_1 β 1 ​ adrenoceptors directly and promotes presynaptic norepinephrine release, augmenting myocardial contractility, heart rate, and cardiac output.

High Dose ( > 10.0 mcg/kg/min >10.0\text{ mcg/kg/min} > 10.0 mcg/kg/min ): α 1 \alpha_1 α 1 ​ adrenoceptor agonism predominates, overcoming dopaminergic vasodilation to cause intense generalized vasoconstriction and elevated SVR.

Fallacy of "Renal-Dose" Dopamine: Extensive multicenter randomized controlled trials (such as the ANZICS trial) demonstrated that low-dose dopamine neither prevents nor mitigates acute kidney injury in critically ill patients. Dopamine is also associated with an increased incidence of tachyarrhythmias (atrial fibrillation, sinus tachycardia, ventricular ectopy) and endocrine suppression (inhibiting anterior pituitary prolactin and thyroid-stimulating hormone release).

Dobutamine

Receptor Profile: Synthetic catecholamine administered as a 50:50 racemic mixture. The ( + ) (+) ( + ) -enantiomer is a potent β 1 \beta_1 β 1 ​ agonist and an α 1 \alpha_1 α 1 ​ antagonist; the ( − ) (-) ( − ) -enantiomer is a selective α 1 \alpha_1 α 1 ​ agonist. When administered clinically, the net result is predominant β 1 \beta_1 β 1 ​ agonism with mild β 2 \beta_2 β 2 ​ and minimal α 1 \alpha_1 α 1 ​ activity ( β 1 > β 2 > α 1 \beta_1 > \beta_2 > \alpha_1 β 1 ​ > β 2 ​ > α 1 ​ ).

Hemodynamic Profile: Powerful inotrope with modest peripheral vasodilation (an "inodilator"). Dobutamine increases cardiac index, stroke volume, and heart rate while lowering left ventricular end-diastolic pressure (LVEDP) and systemic vascular resistance.

Oxygen Demand Hazard: Increases myocardial contractility and heart rate simultaneously, producing an inescapable rise in myocardial oxygen consumption ( M V O 2 MVO_2 M V O 2 ​ ). In patients with fixed coronary artery disease, dobutamine can precipitate acute regional myocardial ischemia and ventricular arrhythmias.

3. Phosphodiesterase-3 (PDE3) Inhibitors: Milrinone and Enoximone

Phosphodiesterase enzymes catalyze the hydrolytic breakdown of cyclic purine nucleotides ( cAMP \text{cAMP} cAMP and cGMP \text{cGMP} cGMP ) into inactive 5'-nucleotide monophosphates. Phosphodiesterase-3 (PDE3) is the primary intracellular isoform expressed in cardiac myocytes and vascular smooth muscle that degrades cAMP \text{cAMP} cAMP . [ PDE3 INHIBITOR MECHANISM ]

  • |
  • Inhibition of Phosphodiesterase-3 (PDE3)
  • |
  • Prevents Hydrolysis: cAMP -> 5'-AMP
  • |
  • +------------------------------+------------------------------+
  • | |
  • [ CARDIAC MYOCYTE ] [ VASCULAR SMOOTH MUSCLE ]
  • Elevated Intracellular cAMP Elevated Intracellular cAMP
  • | |
  • Activates PKA Activates PKA
  • | |
  • Phosphorylates CaV1.2 & Phospholamban Phosphorylates & Inhibits MLCK
  • | |
  • Augments Peak Systolic Ca2+ Influx Reduced Phosphorylation of Myosin Light Chains
  • Accelerates Diastolic SR Ca2+ Reuptake (SERCA2a) Hyperpolarization via BK_Ca Channels
  • | |
  • Positive Inotropy + Enhanced Lusitropy Systemic & Pulmonary Vasodilation
  • | |
  • +------------------------------+------------------------------+
  • |
  • v
  • [ NET INODILATOR EFFECT ]
  • Increased Stroke Volume & Cardiac Index
  • Decreased Left & Right Ventricular Afterload
  • Decreased Pulmonary Vascular Resistance (PVR)
  • Cellular Mechanism

Myocardium: Milrinone and enoximone competitively inhibit PDE3, elevating cytosolic cAMP \text{cAMP} cAMP levels independently of cell-surface beta-receptors. Activation of PKA increases calcium entry through L-type calcium channels during systole and accelerates calcium sequestration via SERCA2a during diastole. This produces positive inotropy and enhanced lusitropy without the receptor down-regulation associated with chronic beta-agonist infusions.

Vascular Smooth Muscle: In systemic resistance vessels and pulmonary arterial beds, elevated cAMP \text{cAMP} cAMP promotes PKA phosphorylation of MLCK, blocking its catalytic activity. Concurrently, PKA activates large-conductance C a 2 + Ca^{2+} C a 2 + -activated K + K^+ K + channels, resulting in marked systemic arterial vasodilation, venodilation, and pulmonary vasodilation .

Clinical Pharmacology and Indications

Inodilator Niche: Milrinone is uniquely suited for patients with acute biventricular failure , low cardiac output states post-cardiopulmonary bypass, and pulmonary hypertension with right ventricular dysfunction . It unloads the right ventricle by reducing pulmonary vascular resistance (PVR) while simultaneously augmenting right ventricular contractile performance.

Myocardial Oxygen Economy: Unlike pure beta-agonists, the marked reduction in ventricular wall tension (afterload reduction) offsets the metabolic cost of enhanced contractility, minimizing net increases in M V O 2 MVO_2 M V O 2 ​ .

Pharmacokinetics and Toxicity: Milrinone is cleared predominantly ( > 85 % >85\% > 85% ) unchanged by renal tubular excretion and glomerular filtration . Its elimination half-life is 2 to 4 hours in healthy subjects but extends up to 10 to 12 hours in acute kidney injury. An intravenous loading bolus ( 50 mcg/kg 50\text{ mcg/kg} 50 mcg/kg ) frequently triggers profound systemic hypotension and should be omitted or drastically reduced in hemodynamically unstable patients; maintenance infusion rates range from 0.375 − 0.75 mcg/kg/min 0.375 - 0.75\text{ mcg/kg/min} 0.375 − 0.75 mcg/kg/min .

4. Calcium Sensitizers: Levosimendan

Levosimendan represents a novel class of inotropic agents operating downstream of intracellular calcium transients, avoiding the cellular calcium overload that characterizes classic sympathomimetics. [ LEVOSIMENDAN MECHANISM ]

  • |
  • +-----------------------------+-----------------------------+
  • | |
  • [ CARDIAC TROPONIN C ] [ VASCULAR SMOOTH MUSCLE ]
  • Binds to Ca2+-saturated Amino-Terminal Opens ATP-Sensitive Potassium
  • Domain of Cardiac Troponin C (cTnC) Channels (K_ATP) on Plasma Membrane
  • | |
  • Stabilizes Active Cross-Bridge Conformation Potassium Efflux -> Hyperpolarization
  • Without Increasing Peak Cytosolic Free Ca2+ Closure of Voltage-Gated L-type Ca2+ Channels
  • | |

Augments Systolic Force (Positive Inotropy) Marked Vasodilation:

  • Preserves Diastolic Relaxation (Neutral Lusitropy) Coronary, Systemic, and Pulmonary Beds
  • Avoids Arrhythmias & Minimizes MVO2 Reduces Preload and Afterload
  • Mechanism of Action

Troponin C Sensitization: Levosimendan binds selectively to the calcium-saturated regulatory domain of cardiac troponin C (cTnC) during systole, stabilizing the conformational shift that permits actin-myosin interaction. Because it detaches from troponin C as intracellular calcium levels fall during diastole, it does not impede diastolic relaxation (preventing impaired lusitropy).

ATP-Sensitive Potassium ( K ATP K_{\text{ATP}} K ATP ​ ) Channel Opening: In vascular smooth muscle and mitochondrial inner membranes, levosimendan activates K ATP K_{\text{ATP}} K ATP ​ channels. The resulting potassium efflux hyperpolarizes the sarcolemma, preventing voltage-gated calcium entry and triggering systemic, pulmonary, and coronary vasodilation .

Mitochondrial Protection: Opening of mitochondrial K ATP K_{\text{ATP}} K ATP ​ channels in cardiomyocytes confers preconditioning-like cardioprotection against ischemia-reperfusion injury.

Pharmacokinetics and Active Metabolites

Parent Drug: Levosimendan has an elimination half-life of approximately 1 hour , metabolized primarily via conjugation with glutathione in the liver and intestinal microflora.

Active Metabolite OR-1896: Approximately 5% of a dose is converted in the large intestine into the intermediate metabolite OR-1855, which is subsequently acetylated in the liver to the active metabolite OR-1896 . OR-1896 possesses identical calcium-sensitizing and vasodilating properties as the parent drug but exhibits an extraordinary elimination half-life of 70 to 80 hours . Consequently, a single 24-hour continuous infusion ( 0.05 − 0.2 mcg/kg/min 0.05 - 0.2\text{ mcg/kg/min} 0.05 − 0.2 mcg/kg/min ) produces sustained hemodynamic and inotropic benefits lasting 7 to 10 days .

5. Arginine Vasopressin (AVP)

Arginine vasopressin is an endogenous nonapeptide hormone synthesized by magnocellular neurosecretory cells in the supraoptic and paraventricular nuclei of the hypothalamus and stored in secretory granules of the posterior pituitary gland (neurohypophysis).

Receptor Classification and Second Messengers

Receptor Subtype Primary Tissue Distribution G-Protein Coupling Second Messenger / Effector Physiological Action

V 1 a V_{1a} V 1 a ​ ( V 1 V_1 V 1 ​ ) Vascular smooth muscle, hepatocytes, platelets G q G_q G q ​ PLC → IP 3 / DAG → ↑ C a 2 + \text{PLC} \rightarrow \text{IP}_3 / \text{DAG} \rightarrow \uparrow Ca^{2+} PLC → IP 3 ​ / DAG →↑ C a 2 + Intense vasoconstriction, glycogenolysis, platelet aggregation

V 1 b V_{1b} V 1 b ​ ( V 3 V_3 V 3 ​ ) Anterior pituitary corticotrophs G q G_q G q ​ PLC → IP 3 → ↑ C a 2 + \text{PLC} \rightarrow \text{IP}_3 \rightarrow \uparrow Ca^{2+} PLC → IP 3 ​ →↑ C a 2 + Stimulates adrenocorticotropic hormone (ACTH) release

V 2 V_2 V 2 ​ Basolateral membrane of renal collecting duct principal cells G s G_s G s ​ Adenylyl cyclase → ↑ cAMP → PKA \rightarrow \uparrow \text{cAMP} \rightarrow \text{PKA} →↑ cAMP → PKA Translocation of Aquaporin-2 water channels to apical membrane → \rightarrow → water reabsorption

Oxytocin ( O T OT OT ) Uterine myometrium, vascular endothelium G q G_q G q ​ PLC → IP 3 → ↑ C a 2 + \text{PLC} \rightarrow \text{IP}_3 \rightarrow \uparrow Ca^{2+} PLC → IP 3 ​ →↑ C a 2 + Myometrial contraction, endothelial NO release

Vasopressin in Acidotic and Refractory Shock

Under physiological conditions, vasopressin plays a minor role in baseline blood pressure regulation. However, during septic shock, cardiopulmonary bypass, and severe hemorrhagic shock, endogenous vasopressin stores are rapidly depleted within hours, leading to a state of relative vasopressin deficiency .

Efficacy in Severe Acidemia: Catecholamines lose their vasopressor potency in severely acidemic environments (arterial pH < 7.20 \text{pH} < 7.20 pH < 7.20 ) because low extracellular pH uncouples β \beta β and α 1 \alpha_1 α 1 ​ adrenoceptors from their respective G-proteins and diminishes intracellular calcium sensitivity. In contrast, V 1 V_1 V 1 ​ receptor signaling remains fully operational during severe acidosis , allowing vasopressin to restore vascular tone when massive doses of norepinephrine fail.

Pulmonary Vascular Sparing: Vasopressin causes powerful systemic arterial constriction, but at clinical doses ( 0.01 − 0.04 units/min 0.01 - 0.04\text{ units/min} 0.01 − 0.04 units/min ), it binds endothelial V 1 V_1 V 1 ​ and oxytocin-like receptors within the pulmonary vascular bed, stimulating the release of endothelial nitric oxide (eNOS) . As a result, vasopressin produces minimal pulmonary vasoconstriction and may even reduce the pulmonary-to-systemic vascular resistance ratio ( P V R / S V R PVR/SVR P V R / S V R ), making it exceptionally valuable in pulmonary hypertension and right ventricular failure.

Clinical Dosing Rule: Vasopressin should be administered as a fixed-dose continuous infusion of 0.01 − 0.04 units/min 0.01 - 0.04\text{ units/min} 0.01 − 0.04 units/min (or 0.03 units/min 0.03\text{ units/min} 0.03 units/min ) without rapid upward titration; higher infusion rates ( > 0.04 − 0.06 units/min >0.04 - 0.06\text{ units/min} > 0.04 − 0.06 units/min ) provoke severe coronary, mesenteric, and cutaneous digital vasoconstriction.

6. Comprehensive Hemodynamic Comparison Table

Drug Target Receptors Inotropy Chronotropy SVR PVR M V O 2 MVO_2 M V O 2 ​ Primary Clinical Application

Epinephrine β 1 , β 2 , α 1 \beta_1, \beta_2, \alpha_1 β 1 ​ , β 2 ​ , α 1 ​ + + + + ++++ + + + + + + + + ++++ + + + + ↓ \downarrow ↓ (low) / ↑ ↑ \uparrow\uparrow ↑↑ (high) ↑ \uparrow ↑ + + + + ++++ + + + + Anaphylaxis, cardiac arrest, cardiogenic shock with low output

Norepinephrine α 1 ≫ β 1 > β 2 \alpha_1 \gg \beta_1 > \beta_2 α 1 ​ ≫ β 1 ​ > β 2 ​ + + ++ + + 0 / + 0 / + 0/ + (reflex ↓ \downarrow ↓ ) + + + + ++++ + + + + ↑ ↑ \uparrow\uparrow ↑↑ + + ++ + + First-line vasopressor in septic and vasodilatory shock

Phenylephrine α 1 \alpha_1 α 1 ​ (pure) 0 0 0 − − -- − − (baroreflex) + + + + ++++ + + + + ↑ \uparrow ↑ + + + Acute drug-induced hypotension with preserved contractility

Ephedrine Indirect α , β \alpha, \beta α , β + direct + + ++ + + + + ++ + + + + ++ + + + + + + + ++ + + Transient hypotension after neuraxial anaesthesia; tachyphylaxis occurs

Dopamine D 1 D_1 D 1 ​ (low), β 1 \beta_1 β 1 ​ (mid), α 1 \alpha_1 α 1 ​ (high) + + + +++ + + + + + + + ++++ + + + + ↓ \downarrow ↓ (low) / ↑ ↑ \uparrow\uparrow ↑↑ (high) + + + + + + + ++++ + + + + Second-line in bradycardic shock; high tachyarrhythmia burden

Dobutamine β 1 > β 2 ≫ α 1 \beta_1 > \beta_2 \gg \alpha_1 β 1 ​ > β 2 ​ ≫ α 1 ​ + + + + ++++ + + + + + + ++ + + ↓ \downarrow ↓ ↓ \downarrow ↓ + + + +++ + + + Cardiogenic shock with preserved blood pressure; low cardiac output

Milrinone PDE3 inhibitor + + + +++ + + + + + + ↓ ↓ \downarrow\downarrow ↓↓ ↓ ↓ \downarrow\downarrow ↓↓ + + + Inodilator for acute decompensated heart failure and pulmonary hypertension

Levosimendan Troponin C + K ATP K_{\text{ATP}} K ATP ​ + + + +++ + + + 0 / + 0 / + 0/ + ↓ ↓ \downarrow\downarrow ↓↓ ↓ ↓ \downarrow\downarrow ↓↓ 0 / + 0 / + 0/ + Cardiogenic shock post-cardiac surgery; active metabolite OR-1896 lasts days

Vasopressin V 1 , V 2 , V 3 V_1, V_2, V_3 V 1 ​ , V 2 ​ , V 3 ​ 0 0 0 0 / − 0 / - 0/ − + + + + ++++ + + + + 0 / ↓ 0 / \downarrow 0/ ↓ + + + Refractory vasodilatory shock; pulmonary hypertension with vasoplegia